Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $4,177.57 today based on a ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...